Haoliang Yuan

机构：China Pharmaceutical University · ORCID：0000-0003-0248-4347

发表论文 90 篇 · 总被引 1677 次 · h-index 24

代表论文

• Discovery of Orally Bioavailable N -Benzylpiperidinol Derivatives as Potent and Selective USP7 Inhibitors with In Vivo Antitumor Immunity Activity against Colon Cancer (2022 · Journal of Medicinal Chemistry · 被引 32)
• Discovery of an Orally Bioavailable STING Inhibitor with In Vivo Anti-Inflammatory Activity in Mice with STING-Mediated Inflammation (2025 · Journal of Medicinal Chemistry · 被引 25)
• Cytochrome P450 3A4 suppression by epimedium and active compound kaempferol leads to synergistic anti-inflammatory effect with corticosteroid (2023 · Frontiers in Pharmacology · 被引 18)
• Discovery of the First Subnanomolar PPARα/δ Dual Agonist for the Treatment of Cholestatic Liver Diseases (2023 · Journal of Medicinal Chemistry · 被引 17)
• Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity (2024 · Journal of Medicinal Chemistry · 被引 15)
• Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors (2023 · Journal of Medicinal Chemistry · 被引 10)